Frontier Medicines Announces FMC-220, the First Covalent p53 Y220C Activator Development Candidate, with Best-in-Class PotentialBOSTON and SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical-stage precision medicine company seeking to unlock the proteome to advance transformational therapies, today announced the selection of FMC-220, the first covalent p53Y220C activator designed to overcome the limitations of potency and durability seen in non-covalent approaches. FMC-220 represents a groundbreaking advancement, with the potential to provide transformative benefits for patients with tumors harboring an important mutant of p53. Preclinical studies demonstrate that FMC-220 delivers unprecedented potency and durable anti-tumor activity both in vitro and in vivo, achieving pronounced tumor regression at low doses. This innovative drug candidate leverages a covalent design to deliver prolonged target engagement, driving durable activation of p53 function inducing tumor cell senescence and importantly, cell death.
Frontier Medicines to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceBOSTON and SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation (“Frontier” or the “Company”), a clinical-stage precision medicine company unlocking to advance transformational therapies, today announced that Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 11:30 a.m. PT.
Frontier Medicines Announces Milestone Payment in AbbVie Partnership, Following Advancement of Lead Candidates Targeting a Historically Undruggable Transcription FactorBOSTON and SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation (“Frontier” or the “Company”), a clinical-stage precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today announced the advancement of lead candidates for further optimization in an AbbVie partnered program targeting a key transcription factor for cancer cell survival, triggering an accompanying milestone payment.
Frontier Medicines Appoints Gerardo Ubaghs as Chief Financial Officer and Announces $20 Million Series C ExtensionBOSTON and SOUTH SAN FRANCISCO, Calif., June 25, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation (“Frontier” or the “Company”), a clinical-stage precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today announced the appointment of Gerardo Ubaghs as Chief Financial Officer (CFO) and the additional close of $20 million extension to its Series C, bringing the total amount raised to $100 million, with the financing slated to accelerate multiple pipeline programs.
Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting- Pre-clinical results demonstrate the combination of FMC-376 with PD-1 immunotherapy increases survival and response rates compared to PD-1 alone
Frontier Medicines to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2024BOSTON and SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical stage precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today announced new preclinical data for FMC-376, a first-in-class direct dual inhibitor of ON+OFF KRASG12C currently being explored in a Phase 1/2 trial, will be shared at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024.
Frontier Medicines to Participate in Upcoming Investor ConferencesBOSTON and SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today announced that Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO, will participate in the upcoming Evercore ISI Emerging Private Biotech Conference, TD Cowen Annual Health Care Conference, and Leerink Partners Global Biopharma Conference.
Frontier Medicines to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceBOSTON and SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today announced that Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 11:30 a.m. PT.
Frontier Medicines Announces Appointment of Andrew Krivoshik, M.D., Ph.D., as Chief Medical OfficerDr. Krivoshik brings two decades of experience successfully leading clinical development teams and programs
Frontier Medicines Presents New Preclinical Data on its Development Candidate, FMC-376, a Dual KRASG12C Inhibitor, at the 2023 AACR Annual Meeting-FMC-376 is a highly selective, direct dual inhibitor designed to rapidly and completely block both the active and inactive forms of KRASG12C and overcome the limitations seen with single-acting inhibitors
Frontier Medicines to Spotlight Lead Candidate, Novel Dual KRASG12C Inhibitor FMC-376, and the Frontier™ Platform at the 2023 AACR Annual MeetingBOSTON and SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthrough therapies against otherwise undruggable disease-causing targets, today announced upcoming presentations featuring preclinical data on its novel dual KRASG12C inhibitor FMC-376 and advances from the Frontier™ Platform. These data will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place April 14th-19th in Orlando, Florida.
Frontier Medicines Expands Leadership Team with Addition of Christo Shalish as Head of Business DevelopmentBOSTON and SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthrough therapies against otherwise undruggable disease-causing targets, today announced the addition of Christo Shalish to the leadership team as senior vice president (SVP) and head of business development.
Frontier Medicines Advances First Development Candidate, FMC-376, a Uniquely Differentiated Inhibitor of Both Active and Inactive KRASG12C, into IND-Enabling StudiesFMC-376 directly, rapidly, and completely blocks both active and inactive forms of KRASG12C to overcome non-response and resistance seen with prior generation KRASG12C inhibitors
Frontier Medicines Announces Advancement of Second and Third Programs Under Global Partnership with AbbVieSOUTH SAN FRANCISCO, Calif. and BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthroughs against otherwise undruggable disease-causing targets, today announced the second and third programs under the company's global partnership with AbbVie have advanced into lead generation. These programs harness novel E3 Ligases for targeted protein degradation, through the discovery of small molecules from The Frontier™ Platform.
Frontier Medicines to Present at the 41st Annual J.P. Morgan Healthcare ConferenceSOUTH SAN FRANCISCO, Calif. and BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company advancing transformative drugs against historically undruggable disease-causing targets, today announced that Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 10:00 a.m. PT.
Frontier Medicines Announces Appointment of Accomplished Finance and Operations Executive, Setareh “SiSi” Pouraghabagher, to Board of DirectorsBOSTON and SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthrough therapies against otherwise undruggable disease-causing targets, today announced the appointment of Setareh “SiSi” Pouraghabagher, CPA, to its board of directors.
Frontier Medicines to Present at Credit Suisse 31st Annual Healthcare ConferenceBOSTON and SOUTH SAN FRANCISCO, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthrough therapies against otherwise undruggable disease-causing targets, today announced that Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO, will participate in a fireside chat at the Credit Suisse 31st Annual Healthcare Conference at 9:10 a.m. PT on November 8, 2022 in Rancho Palos Verdes, CA.
